for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Shenzhen Hepalink Pharma Group Co Ltd

002399.SZ

Latest Trade

15.20CNY

Change

-0.27(-1.75%)

Volume

4,355,883

Today's Range

15.20

 - 

15.63

52 Week Range

15.20

 - 

28.35

As of on the Shenzhen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
15.47
Open
15.50
Volume
4,355,883
3M AVG Volume
121.80
Today's High
15.63
Today's Low
15.20
52 Week High
28.35
52 Week Low
15.20
Shares Out (MIL)
1,247.20
Market Cap (MIL)
18,957.47
Forward P/E
20.27
Dividend (Yield %)
0.66

Latest Developments

More

Shenzhen Hepalink Pharmaceutical's 9-Mth Net Profit Up 48.9% Y/Y

Shenzhen Hepalink Pharmaceutical's H1 Net Profit Up 144.08% Y/Y

Shenzhen Hepalink Pharmaceutical Says Q1 Net Profit Up 636.4 Percent Y/Y

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Shenzhen Hepalink Pharma Group Co Ltd

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD. is a China-based company, principally engaged in the research and development, manufacture and distribution of heparin sodium bulk drugs. The Company primarily offers heparin sodium products, including Food and Drug Administration (FDA) grade heparin sodium ingredients and ordinary grade heparin sodium ingredients. The Company also provides preparations, pancreatin and contract development and manufacturing operations. The Company conducts its business within domestic market and to overseas markets.

Industry

Biotechnology & Drugs

Contact Info

No. 19

Hi-Tech Zhongyi Avenue

Middle Area, Hi-Tech Zone , Nanshan Dist

+86.755.26980311

http://www.hepalink.com

Executive Leadership

Li Li

Chairman of the Board

Bin Zhang

Chief Financial Officer

Xin Qian

Chief Administrative Officer

Yu Shan

General Manager, Director

Haihua Bu

Deputy General Manager, Secretary of the Board

Key Stats

1.50 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2018

4.8K

2019(E)

5.2K
EPS (CNY)

2018

0.494

2019(E)

0.750
Price To Earnings (TTM)
22.66
Price To Sales (TTM)
4.10
Price To Book (MRQ)
2.77
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
92.90
LT Debt To Equity (MRQ)
25.75
Return on Investment (TTM)
9.14
Return on Equity (TTM)
5.78

Latest News

Latest News

BRIEF-Shenzhen Hepalink Pharmaceutical announces change in accounting policy

* Says it changes accounting policy based on accounting standards for business enterprises No. 16—government subsidies, which was disclosed by the Ministry of Finance on May 10, 2017, effective June 12, 2017

BRIEF-Shenzhen Hepalink Pharmaceutical announces 2017 dividend payment

* Says it plans to pay cash dividend of 0.45 yuan per 10 shares (before tax) to the company's shareholders for 2017

BRIEF-Shenzhen Hepalink Pharmaceutical to swing to profit in FY 2018 Q1

* Sees to swing to net profit at 35 million yuan to 52 million yuan in FY 2018 Q1 versus net loss at 12.1 million yuan year ago

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up